# US 2021/0228519 A1 · Methods for treating apoe4/4-associated disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228519 A1
- Document ID: US20210228519A1
- Status: Published application
- Kind: A1
- Application number: 17/046,950
- Filed: 2019-04-12
- Published: 2021-07-29
- Earliest claimed: 2018-04-12
- Assignees: The Regents of the University of California; The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads
- Applicants: The Regents of the University of California; The J. David Gladstone Institutes, A Testamentary Trust Established Under the Will of J. David Glads
- Inventors: Yadong Huang; Alice Taubes; Phil Nova; Marina Sirota
- Web page: https://patentgrep.com/patent/US20210228519A1

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- C07K 14/775: Apolipopeptides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4/4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4/4 genotype by administering bumetanide, and/or instructions and reagents for testing/identifying a subject having an apoE4/4 genotype.

## Claims

### Claim 1

A method of preventing or treating Alzheimer's Disease (AD) in a subject having an apoE4/4 genotype, the method comprising administering a therapeutically effective amount of bumetanide to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering comprises administering bumetanide to the subject at a dose of 0.05 mg/kg/day or less.

### Claim 3 (depends on 2)

The method of claim 2, wherein the administering comprises administering bumetanide to the subject at a dose of 0.02 mg/kg/day or less.

### Claim 4 (depends on 1)

The method of claim 1, wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.

### Claim 5 (depends on 4)

The method of claim 4, wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bumetanide is administered intravenously or parenterally.

### Claim 7 (depends on 1)

The method of claim 1, wherein the bumetanide is provided in a transdermal patch.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mammal is a human.

### Claim 10

A method of preventing or treating Alzheimer's Disease in a subject having an apoE4/4 genotype, the method comprising:
a) identifying a subject as having an apoE4/4 genotype; and
b) administering a therapeutically effective amount of bumetanide to the subject.

### Claim 11 (depends on 10)

The method of claim 10, wherein the identifying comprises performing a PCR-based DNA analytic method on a biological sample from the subject.

### Claim 12 (depends on 11)

The method of claim 11, further comprising isolating the biological sample from the subject.

### Claim 13 (depends on 10)

The method of claim 10, wherein the administering comprises administering bumetanide to the subject as a dose of 0.05 mg/kg/day or less.

### Claim 14 (depends on 13)

The method of claim 13, wherein the administering comprises administering bumetanide to the subject as a dose of 0.02 mg/kg/day or less.

### Claim 15 (depends on 10)

The method of claim 10, wherein the bumetanide is formulated as an oral dosage form comprising a pharmaceutically acceptable carrier, and wherein the oral dosage form is administered orally.

### Claim 16 (depends on 15)

The method of claim 15, wherein the oral dosage form is administered once daily as a capsule, a tablet, a disintegrating tablet or lozenge, or a sachet.

### Claim 17 (depends on 10)

The method of claim 10, wherein the bumetanide is administered intravenously or parenterally.

### Claim 18 (depends on 10)

The method of claim 10, wherein the bumetanide is provided in a transdermal patch.

### Claim 19 (depends on 10)

The method of claim 10, wherein the subject is a mammal.

### Claim 20 (depends on 19)

The method of claim 19, wherein the mammal is a human.

### Claim at position 21

21-42. (canceled)
